Marshall Wace, LLP Brooklyn Immuno Therapeutics, Inc. Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$0.48 - $2.03 $32,367 - $136,886
-67,432 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$1.76 - $4.84 $60,626 - $166,723
34,447 Added 104.43%
67,432 $138,000
Q4 2021

Feb 14, 2022
BUY
$4.17 - $9.79 $137,547 - $322,923
32,985 New
32,985 $138,000

Others Institutions Holding BTX

# of Institutions
1
Shares Held
1.21M
Call Options Held
0
Put Options Held
0
View Full List

About Brooklyn ImmunoTherapeutics, Inc.

BTX Quotes by TradingView
  • Ticker BTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,825,700
  • Description
  • Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...
More about BTX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email